Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.60
LHCG's Cash to Debt is ranked higher than
79% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 0.28 vs. LHCG: 0.60 )
LHCG' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.6

Equity to Asset 0.69
LHCG's Equity to Asset is ranked higher than
88% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. LHCG: 0.69 )
LHCG' s 10-Year Equity to Asset Range
Min: -0.04   Max: 0.82
Current: 0.69

-0.04
0.82
Interest Coverage 23.44
LHCG's Interest Coverage is ranked higher than
84% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 6.09 vs. LHCG: 23.44 )
LHCG' s 10-Year Interest Coverage Range
Min: 7.98   Max: 713.45
Current: 23.44

7.98
713.45
F-Score: 4
Z-Score: 4.60
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.10
LHCG's Operating margin (%) is ranked higher than
70% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. LHCG: 7.10 )
LHCG' s 10-Year Operating margin (%) Range
Min: -1.01   Max: 19.53
Current: 7.1

-1.01
19.53
Net-margin (%) 3.39
LHCG's Net-margin (%) is ranked higher than
68% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 5.38 vs. LHCG: 3.39 )
LHCG' s 10-Year Net-margin (%) Range
Min: -2.09   Max: 10.95
Current: 3.39

-2.09
10.95
ROE (%) 7.63
LHCG's ROE (%) is ranked higher than
71% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 9.51 vs. LHCG: 7.63 )
LHCG' s 10-Year ROE (%) Range
Min: -5.02   Max: 79.1
Current: 7.63

-5.02
79.1
ROA (%) 5.29
LHCG's ROA (%) is ranked higher than
78% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 3.98 vs. LHCG: 5.29 )
LHCG' s 10-Year ROA (%) Range
Min: -3.34   Max: 19.6
Current: 5.29

-3.34
19.6
ROC (Joel Greenblatt) (%) 53.62
LHCG's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 17.97 vs. LHCG: 53.62 )
LHCG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5.87   Max: 133.11
Current: 53.62

-5.87
133.11
Revenue Growth (%) 3.50
LHCG's Revenue Growth (%) is ranked higher than
67% of the 180 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. LHCG: 3.50 )
LHCG' s 10-Year Revenue Growth (%) Range
Min: 3.5   Max: 60.8
Current: 3.5

3.5
60.8
EBITDA Growth (%) -17.20
LHCG's EBITDA Growth (%) is ranked higher than
53% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. LHCG: -17.20 )
LHCG' s 10-Year EBITDA Growth (%) Range
Min: -64.8   Max: 79.5
Current: -17.2

-64.8
79.5
EPS Growth (%) -21.40
LHCG's EPS Growth (%) is ranked higher than
58% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 9.30 vs. LHCG: -21.40 )
LHCG' s 10-Year EPS Growth (%) Range
Min: -21.4   Max: 116.3
Current: -21.4

-21.4
116.3
» LHCG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

LHCG Guru Trades in Q1 2013

Chuck Royce 11,800 sh (New)
Joel Greenblatt 35,475 sh (New)
Richard Snow Sold Out
Jim Simons Sold Out
» More
Q2 2013

LHCG Guru Trades in Q2 2013

Steven Cohen 104,267 sh (New)
Chuck Royce 25,000 sh (+111.86%)
Joel Greenblatt 60,501 sh (+70.55%)
» More
Q3 2013

LHCG Guru Trades in Q3 2013

Jim Simons 8,700 sh (New)
Joel Greenblatt 84,045 sh (+38.92%)
Steven Cohen Sold Out
Chuck Royce Sold Out
» More
Q4 2013

LHCG Guru Trades in Q4 2013

Jim Simons 9,888 sh (+13.66%)
Joel Greenblatt 81,294 sh (-3.27%)
» More
» Details

Insider Trades

Latest Guru Trades with LHCG

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-09-30 Add 38.92%0.02%$19.3 - $26.49 $ 21.32-7%84045
Joel Greenblatt 2013-06-30 Add 70.55%0.02%$19.58 - $23.5 $ 21.32-3%60501
Joel Greenblatt 2013-03-31 New Buy0.04%$20.08 - $22.67 $ 21.321%35475
Michael Price 2012-12-31 Sold Out 0.2%$16.33 - $22.12 $ 21.3214%0
Michael Price 2012-06-30 Add 281.58%0.13%$16.29 - $18.83 $ 21.3222%72500
Joel Greenblatt 2012-03-31 Sold Out 0.09%$12.57 - $19.71 $ 21.3238%0
Michael Price 2012-03-31 New Buy0.05%$12.57 - $19.71 $ 21.3238%19000
Joel Greenblatt 2011-09-30 Add 112.78%0.08%$16.15 - $23.9 $ 21.327%52218
Joel Greenblatt 2011-03-31 Add 179.18%0.17%$26.33 - $31.52 $ 21.32-26%29278
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.40
LHCG's P/E(ttm) is ranked higher than
83% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 21.80 vs. LHCG: 16.40 )
LHCG' s 10-Year P/E(ttm) Range
Min: 6.45   Max: 33.22
Current: 16.4

6.45
33.22
P/B 1.30
LHCG's P/B is ranked higher than
87% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 2.29 vs. LHCG: 1.30 )
LHCG' s 10-Year P/B Range
Min: 0.88   Max: 4.66
Current: 1.3

0.88
4.66
P/S 0.60
LHCG's P/S is ranked higher than
82% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.37 vs. LHCG: 0.60 )
LHCG' s 10-Year P/S Range
Min: 0.35   Max: 2.36
Current: 0.6

0.35
2.36
PFCF 9.70
LHCG's PFCF is ranked higher than
84% of the 165 Companies
in the Global Medical Care industry.

( Industry Median: 15.52 vs. LHCG: 9.70 )
LHCG' s 10-Year PFCF Range
Min: 3.89   Max: 112.88
Current: 9.7

3.89
112.88
EV-to-EBIT 8.40
LHCG's EV-to-EBIT is ranked higher than
93% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 17.82 vs. LHCG: 8.40 )
LHCG' s 10-Year EV-to-EBIT Range
Min: 3.8   Max: 161.2
Current: 8.4

3.8
161.2
Shiller P/E 12.60
LHCG's Shiller P/E is ranked higher than
90% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 24.97 vs. LHCG: 12.60 )
LHCG' s 10-Year Shiller P/E Range
Min: 7.67   Max: 18.23
Current: 12.6

7.67
18.23

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.20
LHCG's Price/Tangible Book is ranked lower than
82% of the 142 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. LHCG: 10.20 )
LHCG' s 10-Year Price/Tangible Book Range
Min: 5.53   Max: 19.15
Current: 10.2

5.53
19.15
Price/DCF (Projected) 0.50
LHCG's Price/DCF (Projected) is ranked higher than
92% of the 122 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. LHCG: 0.50 )
LHCG' s 10-Year Price/DCF (Projected) Range
Min: 0.34   Max: 0.74
Current: 0.5

0.34
0.74
Price/Median PS Value 0.60
LHCG's Price/Median PS Value is ranked higher than
92% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. LHCG: 0.60 )
LHCG' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 2.29
Current: 0.6

0.38
2.29
Price/Graham Number 2.40
LHCG's Price/Graham Number is ranked lower than
52% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 2.20 vs. LHCG: 2.40 )
LHCG' s 10-Year Price/Graham Number Range
Min: 1.81   Max: 3.61
Current: 2.4

1.81
3.61
Earnings Yield (Greenblatt) 11.90
LHCG's Earnings Yield (Greenblatt) is ranked higher than
92% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 5.50 vs. LHCG: 11.90 )
LHCG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 26.1
Current: 11.9

0.6
26.1
Forward Rate of Return (Yacktman) 10.15
LHCG's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 169 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. LHCG: 10.15 )
LHCG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.6   Max: 40.3
Current: 10.15

8.6
40.3

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:LH6.Germany
LHC Group, Inc., provides post-acute health care services to patients through its home nursing agencies, hospices, and long-term acute care hospitals (LTACHs) in the United States. Through its wholly and majority owned subsidiaries, equity joint ventures and controlled affiliates, it currently operates in several states. The company operates in two segments: home-based services and facility-based services. As of December 31, 2012, it owned and operated 274 home-based service locations, with 232 home nursing agency locations, 32 hospices, three specialty agencies and four private duty agencies. As of December 31, 2012, it also managed the operations of three home nursing agencies in which it do not have an ownership interest. Its facility-based services included six long-term acute care hospitals with nine locations, a pharmacy, and a family health center. It provides home-based post-acute health care services through its home nursing agencies and hospices. Its home nursing locations offer a wide range of services, including skilled nursing, medically-oriented social services and physical, occupational and speech therapy. The nurses, home health aides and therapists in its home nursing agencies work closely with patients and their families to design and implement individualized treatments in accordance with a physician-prescribed plan of care. Its hospices provide end-of-life care to patients with terminal illnesses through interdisciplinary teams of physicians, nurses, home health aides, counselors and volunteers. Of the 274 home-based services locations, 140 are wholly-owned by it, 124 are majority-owned or controlled by it through joint ventures, seven are operated through license lease arrangements, and it manage the operations of three home nursing agencies in which it have no ownership interest. Its LTACH locations provide services primarily to patients with complex medical conditions who have transitioned out of a hospital intensive care unit but whose conditions remain too severe for treatment in a non-acute setting. As of December 31, 2012, its LTACHs had 220 licensed beds. Of its 11 facility-based services locations, six are wholly-owned by it and five are majority-owned or controlled by it through joint ventures. The Company is subject to both federal and state income tax for jurisdictions within which it operates.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide